Poseida Therapeutics, Inc. (PSTX)
Stock Price:
$12.83 USD
0.15 (1.18%)
Updated Aug 7, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
793.10M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-86.53M |
| Shares Out |
n/a |
| EPS (ttm) |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 7, 2020 |
| Last Price |
$12.83 |
| Previous Close |
$12.68 |
| Change ($) |
0.15 |
| Change (%) |
1.18% |
| Day's Open |
12.56 |
| Day's Range |
12.45 - 13.18 |
| Day's Volume |
225,484 |
| 52-Week Range |
11.35 - 17.62 |
More Stats
| Market Cap |
793.10M |
| Enterprise Value |
696.92M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
n/a |
| Float |
n/a |
| EPS (basic) |
n/a |
| EPS (diluted) |
n/a |
| FCF / Share |
-5.51 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
n/a |
| Short Ratio |
n/a |
| Short % of Float |
n/a |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
n/a |
| Revenue |
n/a |
| Operating Income |
-85.53M |
| Net Income |
-86.53M |
| Free Cash Flow |
-69.55M |
| Net Cash |
96.18M |
| Net Cash / Share |
n/a |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
n/a |
| ROE |
n/a |
| ROIC |
-217.80% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (3)
| Buy |
3 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$29.67*
(131.25% upside)
Low
20.0
Current: $12.83
High
39.0
Target: 29.67
*Average 12-month price target from 3 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 |
|---|
| Revenue | - | - |
| Operating Income | -85.53 | -41.99 |
| Net Income | -86.53 | -44.40 |
| Shares Outstanding | 12.62 | 12.18 |
| Earnings Per Share | -6.86 | -3.64 |
| Operating Cash Flow | -64.39 | -38.01 |
| Capital Expenditures | -5.16 | -1.28 |
| Free Cash Flow | -69.55 | -39.30 |
| Cash & Equivalents | 125 | 30.40 |
| Total Debt | 29.14 | 19.09 |
| Net Cash / Debt | 96.18 | 11.31 |
| Assets | 147 | 45.12 |
| Liabilities | 74.33 | 49.38 |
| Book Value | -150 | -76.72 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Poseida Therapeutics, Inc. |
| Country |
United States |
| Employees |
149 |
| CEO |
Eric M. Ostertag |
Stock Information
| Ticker Symbol |
PSTX |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: PSTX |
| IPO Date |
July 10, 2020 |
Description
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company is developing a pipeline of solutions for the treatment of hematological malignancies and solid tumors, as well as vivo programs for liver-directed gene therapies for rare diseases. In addition, it offers CAR-T therapies for the treatment for cancer. Further, it offers gene therapies for rare and life-threatening diseases, including Ornithine transcarbamylase (OTC) deficiency and methylmalonic acidemia (MMA), and genetic liver diseases. The company was founded in 2014 and is headquartered in San Diego, California.